The global cardiovascular therapeutics market in 2017 was estimated at USD 129 billion and projected to grow at CAGR of 2.3% to reach USD 141.38 billion by 2021. The top 10 cardiovascular drugs accounted for revenue of USD 11.55 billion in 2017. AstraZeneca/Shionogi /Chiesi, dominates the cardiovascular market, with its best-selling product, Crestor/Provisacor.
Sources: SEC filings, companies websites, and annual reports.
Luca Dezzani is a Novartis employee. All the views, analysis, and perspectives are fully independent and belongs to the author only. They do not represent the views or opinions of Novartis or any other company or organization. IgeaHub is a pharmaceutical blog created and curated by Luca Dezzani. IgeaHub does not receive any funding or support from Novartis or any other pharmaceutical company.